A 45-day randomized, open-label, comparator study to evaluate the safety and efficacy of zincovit tablets with grape seed extract (Nutritional food supplement) in patients with type 2 diabetes mellitus

Yeshwanth Rao, Sudha Vidyasagar, K. Laxminarayana Bairy

Research output: Contribution to journalArticle

Abstract

Objective: To evaluate the efficacy of Zincovit (ZVT) tablets with grape seed extract (GSE) in patients with Type 2 diabetes mellitus by testing the hypothesis of a greater reduction in plasma glucose levels (fasting blood sugar[FBS] and post-prandial blood sugar [PPBS]) from baseline and after 45 days of therapy as compared to standard comparator. Methods: This was a randomized, open-label, comparative (2-arm), prospective 45 days study. Treatment consisted of 2 arms: Antidiabetic drug plus non-pharmacological measure alone or ZVT tablets with GSE plus non-pharmacological measures. A total of 30 patients (15 in each arm) were included in the study. Results: ZVT tablet did not alter the FBS, PPBS, and HbA1c level in diabetic patients compared to diabetic patients treated with placebo. No changes were seen in any of the safety parameters when given for 45 days. Conclusion: ZVT tablets do not possess antidiabetic activity in spite of good safety profile in our study design. This could be due to several limitations of the study such as inadequate sample size, short duration of the study, and wrong selection of the patients. A long-term, double-blind, placebo controlled study in a large sample of population measuring glycemic parameters, and cardiovascular outcomes could give a clear picture of the anti-diabetic effect of ZVT with GSE tablets.

Original languageEnglish
Pages (from-to)220-222
Number of pages3
JournalAsian Journal of Pharmaceutical and Clinical Research
Volume9
Issue number2
Publication statusPublished - 01-03-2016

Fingerprint

Grape Seed Extract
Dietary Supplements
Type 2 Diabetes Mellitus
Tablets
Blood Glucose
Safety
Hypoglycemic Agents
Meals
Fasting
Placebos
Sample Size
Patient Selection
Glucose
Therapeutics
Population

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Pharmaceutical Science
  • Pharmacology (medical)

Cite this

@article{0a3aa863be3f425296248eac5d415b9f,
title = "A 45-day randomized, open-label, comparator study to evaluate the safety and efficacy of zincovit tablets with grape seed extract (Nutritional food supplement) in patients with type 2 diabetes mellitus",
abstract = "Objective: To evaluate the efficacy of Zincovit (ZVT) tablets with grape seed extract (GSE) in patients with Type 2 diabetes mellitus by testing the hypothesis of a greater reduction in plasma glucose levels (fasting blood sugar[FBS] and post-prandial blood sugar [PPBS]) from baseline and after 45 days of therapy as compared to standard comparator. Methods: This was a randomized, open-label, comparative (2-arm), prospective 45 days study. Treatment consisted of 2 arms: Antidiabetic drug plus non-pharmacological measure alone or ZVT tablets with GSE plus non-pharmacological measures. A total of 30 patients (15 in each arm) were included in the study. Results: ZVT tablet did not alter the FBS, PPBS, and HbA1c level in diabetic patients compared to diabetic patients treated with placebo. No changes were seen in any of the safety parameters when given for 45 days. Conclusion: ZVT tablets do not possess antidiabetic activity in spite of good safety profile in our study design. This could be due to several limitations of the study such as inadequate sample size, short duration of the study, and wrong selection of the patients. A long-term, double-blind, placebo controlled study in a large sample of population measuring glycemic parameters, and cardiovascular outcomes could give a clear picture of the anti-diabetic effect of ZVT with GSE tablets.",
author = "Yeshwanth Rao and Sudha Vidyasagar and {Laxminarayana Bairy}, K.",
year = "2016",
month = "3",
day = "1",
language = "English",
volume = "9",
pages = "220--222",
journal = "Asian Journal of Pharmaceutical and Clinical Research",
issn = "0974-2441",
publisher = "Innovare Academics Sciences Pvt. Ltd",
number = "2",

}

TY - JOUR

T1 - A 45-day randomized, open-label, comparator study to evaluate the safety and efficacy of zincovit tablets with grape seed extract (Nutritional food supplement) in patients with type 2 diabetes mellitus

AU - Rao, Yeshwanth

AU - Vidyasagar, Sudha

AU - Laxminarayana Bairy, K.

PY - 2016/3/1

Y1 - 2016/3/1

N2 - Objective: To evaluate the efficacy of Zincovit (ZVT) tablets with grape seed extract (GSE) in patients with Type 2 diabetes mellitus by testing the hypothesis of a greater reduction in plasma glucose levels (fasting blood sugar[FBS] and post-prandial blood sugar [PPBS]) from baseline and after 45 days of therapy as compared to standard comparator. Methods: This was a randomized, open-label, comparative (2-arm), prospective 45 days study. Treatment consisted of 2 arms: Antidiabetic drug plus non-pharmacological measure alone or ZVT tablets with GSE plus non-pharmacological measures. A total of 30 patients (15 in each arm) were included in the study. Results: ZVT tablet did not alter the FBS, PPBS, and HbA1c level in diabetic patients compared to diabetic patients treated with placebo. No changes were seen in any of the safety parameters when given for 45 days. Conclusion: ZVT tablets do not possess antidiabetic activity in spite of good safety profile in our study design. This could be due to several limitations of the study such as inadequate sample size, short duration of the study, and wrong selection of the patients. A long-term, double-blind, placebo controlled study in a large sample of population measuring glycemic parameters, and cardiovascular outcomes could give a clear picture of the anti-diabetic effect of ZVT with GSE tablets.

AB - Objective: To evaluate the efficacy of Zincovit (ZVT) tablets with grape seed extract (GSE) in patients with Type 2 diabetes mellitus by testing the hypothesis of a greater reduction in plasma glucose levels (fasting blood sugar[FBS] and post-prandial blood sugar [PPBS]) from baseline and after 45 days of therapy as compared to standard comparator. Methods: This was a randomized, open-label, comparative (2-arm), prospective 45 days study. Treatment consisted of 2 arms: Antidiabetic drug plus non-pharmacological measure alone or ZVT tablets with GSE plus non-pharmacological measures. A total of 30 patients (15 in each arm) were included in the study. Results: ZVT tablet did not alter the FBS, PPBS, and HbA1c level in diabetic patients compared to diabetic patients treated with placebo. No changes were seen in any of the safety parameters when given for 45 days. Conclusion: ZVT tablets do not possess antidiabetic activity in spite of good safety profile in our study design. This could be due to several limitations of the study such as inadequate sample size, short duration of the study, and wrong selection of the patients. A long-term, double-blind, placebo controlled study in a large sample of population measuring glycemic parameters, and cardiovascular outcomes could give a clear picture of the anti-diabetic effect of ZVT with GSE tablets.

UR - http://www.scopus.com/inward/record.url?scp=84960077334&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84960077334&partnerID=8YFLogxK

M3 - Article

VL - 9

SP - 220

EP - 222

JO - Asian Journal of Pharmaceutical and Clinical Research

JF - Asian Journal of Pharmaceutical and Clinical Research

SN - 0974-2441

IS - 2

ER -